Breaking News

Telix to Acquire Pipeline, Technology Platform & Facility from ImaginAb

Enables Telix to explore new disease areas with state-of-the-art radiotherapeutic technology.

Author Image

By: Charlie Sternberg

Associate Editor

Telix Pharmaceuticals Limited has entered into an asset purchase agreement with antibody engineering company ImaginAb Inc. to acquire a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility to enhance existing innovation capabilities. This is the latest acquisition from Telix, which also agreed to acquire RLS, a Joint Commission-accredited radiopharmacy network in September. Pipeline ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics